Gennady Poda

Citado por

	Total	Desde 2019
Citas	4682	2307
Índice h	32	23
Índice i10	54	34

440

220

110

330

19981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202414 14 26 17 18 27 23 25 37 54 79 123 136 126 152 161 180 210 259 298 314 316 318 411 432 396 427

Acceso público

Ver todo

29 artículos

10 artículos

disponibles

no disponibles

Basado en requisitos de financiación

Coautores

Igor V. TetkoBIGCHEM GmbH & Helmholtz MunichDirección de correo verificada de helmholtz-munich.de
$Vsevolod Y. Tanchuk \ Всеволод Танчук$ Vsevolod Y. Tanchuk \ Всеволод Тан...IBOPC, Інститут біоорганічної хімії та нафтохімії НАН УкраїниDirección de correo verificada de bpci.kiev.ua
Marvin J MeyersAssociate Professor of Chemistry, Saint Louis UniversityDirección de correo verificada de slu.edu
Matthieu SchapiraAssociate Professor, University of TorontoDirección de correo verificada de utoronto.ca
Masoud VedadiUniversity of TorontoDirección de correo verificada de utoronto.ca
Cheryl ArrowsmithSenior Scientist, Princess Margaret Cancer Centre & Professor of Medical Biophysics, University of TorontoDirección de correo verificada de uhnres.utoronto.ca
Peter J BrownDirección de correo verificada de mindspring.com
frank sicheriLunenfeld-Tanenbaum Research Institute, Mount Sinai HospitalDirección de correo verificada de lunenfeld.ca
Ioannis PrassasScientist, Pathology @ UHN (University Health Network) - TorontoDirección de correo verificada de utoronto.ca
Eleftherios DiamandisProfessor of Laboratory Medicine and Pathobiology, University of TorontoDirección de correo verificada de mtsinai.on.ca
David ChiovittiSamuel Lunenfeld Research Institute Dirección de correo verificada de lunenfeld.ca
Daniel DurocherThe Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital and Department of MolecularDirección de correo verificada de lunenfeld.ca
David M FergusonProfessor of Medicinal Chemistry University of MinnesotaDirección de correo verificada de umn.edu
Lionel MoulédousCNRS Researcher (CR1), CRCA (CNRS-UT3), TMBI (Univ. Toulouse)Dirección de correo verificada de univ-tlse3.fr
Werner MewesProfessor of Bioinformatics (retired), Technische Univ. MünchenDirección de correo verificada de mytum.de
Girinath G. PillaiLead Scientist, Sygnature Discovery, UKDirección de correo verificada de sygnaturediscovery.com
Yurii SushkoGoogleDirección de correo verificada de google.com
Vladimir PotemkinSouth Ural State UniversityDirección de correo verificada de susu.ru
Azza EissaUniversity of TorontoDirección de correo verificada de utoronto.ca
Carly GriffinToronto, WindsorDirección de correo verificada de utoronto.ca

Seguir

Gennady Poda

PhD, Scientific Advisor & Group Leader, Computational Chemistry and Chemoinformatics, OICR

Dirección de correo verificada de oicr.on.ca

Computational Chemistry Cheminformatics Structure-Based Drug Design In Silico ADMET property prediction Medicinal Chemistry


Título Ordenar por citas Ordenar por año Ordenar por título	Citado por Citado por	Año
Calculation of molecular lipophilicity: State-of-the-art and comparison of log P methods on more than 96,000 compounds R Mannhold, GI Poda, C Ostermann, IV Tetko Journal of pharmaceutical sciences 98 (3), 861-893, 2009	731	2009
Can we estimate the accuracy of ADME–Tox predictions? IV Tetko, P Bruneau, HW Mewes, DC Rohrer, GI Poda Drug discovery today 11 (15-16), 700-707, 2006	311	2006
Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia F Grebien, M Vedadi, M Getlik, R Giambruno, A Grover, R Avellino, ... Nature chemical biology 11 (8), 571-578, 2015	302	2015
ToxAlerts: a web server of structural alerts for toxic chemicals and compounds with potential adverse reactions I Sushko, E Salmina, VA Potemkin, G Poda, IV Tetko Journal of chemical information and modeling 52 (8), 2310-2316, 2012	259	2012
Unleashing the therapeutic potential of human kallikrein-related serine proteases I Prassas, A Eissa, G Poda, EP Diamandis Nature reviews Drug discovery 14 (3), 183-202, 2015	256	2015
Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2) DR Anderson, MJ Meyers, WF Vernier, MW Mahoney, RG Kurumbail, ... Journal of medicinal chemistry 50 (11), 2647-2654, 2007	196	2007
Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5 G Senisterra, H Wu, A Allali-Hassani, GA Wasney, D Barsyte-Lovejoy, ... Biochemical Journal 449 (1), 151-159, 2013	175	2013
Application of ALOGPS 2.1 to predict log D distribution coefficient for Pfizer proprietary compounds IV Tetko, GI Poda Journal of medicinal chemistry 47 (23), 5601-5604, 2004	155	2004
Structure and mechanism of action of the hydroxy–aryl–aldehyde class of IRE1 endoribonuclease inhibitors M Sanches, NM Duffy, M Talukdar, N Thevakumaran, D Chiovitti, ... Nature communications 5 (1), 4202, 2014	141	2014
Applications of neural networks in structure-activity relationships of a small number of molecules IV Tetko, AI Luik, GI Poda Journal of medicinal chemistry 36 (7), 811-814, 1993	131	1993
A new, improved hybrid scoring function for molecular docking and scoring based on AutoDock and AutoDock Vina VY Tanchuk, VO Tanin, AI Vovk, G Poda Chemical biology & drug design 87 (4), 618-625, 2016	128	2016
Functional characterization of a PROTAC directed against BRAF mutant V600E G Posternak, X Tang, P Maisonneuve, T Jin, H Lavoie, S Daou, S Orlicky, ... Nature chemical biology 16 (11), 1170-1178, 2020	110	2020
An Allosteric Inhibitor of Protein Arginine Methyltransferase 3 A Siarheyeva, G Senisterra, A Allali-Hassani, A Dong, E Dobrovetsky, ... Structure, 2012	104	2012
Structure-based optimization of a small molecule antagonist of the interaction between WD repeat-containing protein 5 (WDR5) and mixed-lineage leukemia 1 (MLL1) M Getlik, D Smil, C Zepeda-Velazquez, Y Bolshan, G Poda, H Wu, A Dong, ... Journal of medicinal chemistry 59 (6), 2478-2496, 2016	97	2016
Molecular modelling of the ORL1 receptor and its complex with nociceptin. CM Topham, L Moulédous, G Poda, B Maigret, JC Meunier Protein engineering 11 (12), 1163-1179, 1998	97	1998
Synthesis, optimization, and evaluation of novel small molecules as antagonists of WDR5-MLL interaction Y Bolshan, M Getlik, E Kuznetsova, GA Wasney, T Hajian, G Poda, ... ACS medicinal chemistry letters 4 (3), 353-357, 2013	81	2013
Discovery of an MLLT1/3 YEATS domain chemical probe M Moustakim, T Christott, OP Monteiro, J Bennett, C Giroud, J Ward, ... Angewandte Chemie International Edition 57 (50), 16302-16307, 2018	80	2018
Condensation-driven assembly of boron-containing bis (heteroaryl) motifs using a linchpin approach S Adachi, SK Liew, CF Lee, A Lough, Z He, JDS Denis, G Poda, AK Yudin Organic letters 17 (22), 5594-5597, 2015	79	2015
Reconstitution and characterization of eukaryotic N6-threonylcarbamoylation of tRNA using a minimal enzyme system LCK Wan, DYL Mao, D Neculai, J Strecker, D Chiovitti, I Kurinov, G Poda, ... Nucleic acids research 41 (12), 6332-6346, 2013	77	2013
Benzothiophene inhibitors of MK2. Part 2: Improvements in kinase selectivity and cell potency DR Anderson, MJ Meyers, RG Kurumbail, N Caspers, GI Poda, SA Long, ... Bioorganic & Medicinal Chemistry Letters 19 (16), 4882-4884, 2009	69	2009

El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.

Artículos 1–20

Citas por año

Citas duplicadas

Citas combinadas

Añadir coautoresCoautores

Seguir

Citado por

Coautores